Cardio Restore's liquid formula contains 90% EDTA. EDTA binds or chelates with heavy metals and minerals that are present in the bloodstream and in the walls of blood vessels. Calcium is the main target and is thought to be the biggest contributor to circulatory problems. Too much calcium can cause blood vessels to become calcified and hard, resulting in restricted blood flow. When this occurs, blood cannot be distributed properly to its intended body parts for proper nourishment. As the EDTA dissolves the calcium, it softens the hardened plaque and cholesterol and passes the chelated material out of your body through your urine.

EDTA is recognized by the body as an amino acid, therefore it is allowed to flow freely through-out your entire cardiovascular system. As a result of EDTA's effectiveness at binding to heavy metals and minerals throughout your body, the brain, legs, heart and the rest of your cardiovascular system's circulation improves. EDTA chelation therapy will not only improve and repair small blood vessels, but it will help in promoting the growth of new blood vessels.
 

Studies of EDTA

Is EDTA safe? Several studies have been done on EDTA chelation and its safety has been proven with thousands of patients. EDTA has been administered several different ways, all over the world and numerous people have been helped. Below are some studies on EDTA Chelation.

Study 1

In 1988, Olszewer and Carter conducted a study involving 2,870 patients who were suffering from various chronic degenerative diseases, but primarily vascular disease. Nearly 90% of the patients showed good to excellent improvement, measured primarily by walking distance. This same group also completed a small blinded, crossover study with peripheral vascular sufferers who, after treatment with EDTA chelation therapy, showed particularly significant improvement in walking distance and ankle/brachial index measurements. (Olszewer, Carter, 41-9)

Study 2

In 1993, Hanke and Flytlie treated 65 patients with EDTA chelation therapy who were waiting for bypass surgery for an average of six months. 89% of these people who were waiting for the surgery were able to cancel their operation because there were significant improvements with EDTA chelation. The study concluded that of the 27 people that were scheduled for amputation, 24 patient's limbs were saved.

Study 3

Results of a 1994 study conducted by Van Rij and his associates compared EDTA and thiamin/ascorbate treatment for peripheral vascular disease. The results showed EDTA had a 60% improvement rate. Most importantly, the patients in this study who underwent the parameters, including resting ankle/brachial indices in both better and worse legs. 26% of the EDTA chelation group achieved 100% improvement in walking distance, compared with only 12% with the thiamin group. Among non smokers, 66% of the EDTA group bettered their walking distance by 86%, but only 45% of their subjects bettered their walking by 55%. (C.M. Hawken, 21-22)

Study 4

Currently, the National Institutes of Health is conducting the largest clinical trial on EDTA Chelation and its effect on coronary artery disease. This study includes over 2,300 patients throughout the United States and is expected to be completed in 2008. Review the study here.